TISIDB

Summary
Symbol	IQGAP3
Name	IQ motif containing GTPase activating protein 3
Aliases	Ras GTPase-activating-like protein IQGAP3
Chromosomal Location	1q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF00307 Calponin homology (CH) domain PF00612 IQ calmodulin-binding motif PF00616 GTPase-activator protein for Ras-like GTPase PF03836 RasGAP C-terminus
Function	-

> Gene Ontology [ TOP ]
Biological Process	GO:0000082 G1/S transition of mitotic cell cycle GO:0000187 activation of MAPK activity GO:0007265 Ras protein signal transduction GO:0008361 regulation of cell size GO:0030879 mammary gland development GO:0032147 activation of protein kinase activity GO:0032535 regulation of cellular component size GO:0033598 mammary gland epithelial cell proliferation GO:0033599 regulation of mammary gland epithelial cell proliferation GO:0033601 positive regulation of mammary gland epithelial cell proliferation GO:0033674 positive regulation of kinase activity GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044843 cell cycle G1/S phase transition GO:0045860 positive regulation of protein kinase activity GO:0048732 gland development GO:0050673 epithelial cell proliferation GO:0050678 regulation of epithelial cell proliferation GO:0050679 positive regulation of epithelial cell proliferation GO:0061180 mammary gland epithelium development GO:0070371 ERK1 and ERK2 cascade GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:0090066 regulation of anatomical structure size
Molecular Function	GO:0005516 calmodulin binding GO:0017016 Ras GTPase binding GO:0017022 myosin binding GO:0017048 Rho GTPase binding GO:0031267 small GTPase binding GO:0032027 myosin light chain binding GO:0051020 GTPase binding GO:0070853 myosin VI binding GO:0070856 myosin VI light chain binding
Cellular Component	GO:0016328 lateral plasma membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04810 Regulation of actin cytoskeleton
Reactome	R-HSA-195258: RHO GTPase Effectors R-HSA-5626467: RHO GTPases activate IQGAPs R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases

Summary
Symbol	IQGAP3
Name	IQ motif containing GTPase activating protein 3
Aliases	Ras GTPase-activating-like protein IQGAP3
Chromosomal Location	1q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between IQGAP3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	IQGAP3
Name	IQ motif containing GTPase activating protein 3
Aliases	Ras GTPase-activating-like protein IQGAP3
Chromosomal Location	1q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of IQGAP3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	IQGAP3
Name	IQ motif containing GTPase activating protein 3
Aliases	Ras GTPase-activating-like protein IQGAP3
Chromosomal Location	1q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of IQGAP3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.73	0.0199
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.008	0.407
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.525	0.56
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.686	0.181
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.657	0.73
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.733	0.782
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.052	0.903
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.377	0.782
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.646	0.634
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.271	0.714
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.003	0.998
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.502	0.00057

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of IQGAP3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	1.4	9.7	0.0589
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	1.7	9.4	0.0895
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	44.4	6.2	38.2	0.0403
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	60	0	60	0.0275
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	14.3	10.7	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	7.4	0.5	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	15.4	-1.8	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	IQGAP3
Name	IQ motif containing GTPase activating protein 3
Aliases	Ras GTPase-activating-like protein IQGAP3
Chromosomal Location	1q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IQGAP3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	IQGAP3
Name	IQ motif containing GTPase activating protein 3
Aliases	Ras GTPase-activating-like protein IQGAP3
Chromosomal Location	1q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IQGAP3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IQGAP3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	IQGAP3
Name	IQ motif containing GTPase activating protein 3
Aliases	Ras GTPase-activating-like protein IQGAP3
Chromosomal Location	1q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IQGAP3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	IQGAP3
Name	IQ motif containing GTPase activating protein 3
Aliases	Ras GTPase-activating-like protein IQGAP3
Chromosomal Location	1q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of IQGAP3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	IQGAP3
Name	IQ motif containing GTPase activating protein 3
Aliases	Ras GTPase-activating-like protein IQGAP3
Chromosomal Location	1q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between IQGAP3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	IQGAP3
Name	IQ motif containing GTPase activating protein 3
Aliases	Ras GTPase-activating-like protein IQGAP3
Chromosomal Location	1q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting IQGAP3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse IQGAP3